Why the FDA Is Slow to Remove Drugs

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. Cookies are small text files that can be used by websites to make a user's experience more efficient.The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission.This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.You can at any time change or withdraw your consent from the Cookie Declaration on our website.Learn more about who we are, how you can

Back to Articles Back to Articles Why the FDA Is Slow to Remove Drugs Words by Michael DePeau-Wilson Long Read Issue 08 Back to Articles Why the FDA Is Slow to Remove Drugs On the 90-year saga of oral phenylephrine. Example H2 Example H3 For millennia, our ancestors sought every imaginable cure for the common cold, from ancient Greeks who boiled hyssop with figs, water, honey, and rue, to the 15th-century English , who made a remedy by brewing “stale ale, mustard seeds, and ground nutmeg.” Despite such efforts, generation after generation continued to suffer from nasal congestion without any e

saved by

• Anindya Barua

related reading

• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• Reputation (FDA’s Version)—Asteriskasteriskmag.com
• The Secret Gamble at the FDA That Exposed Americans to Risky Drugs — ProPublicapropublica.org
• Who regulates the regulators?rootsofprogress.org
• Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness - PubMedpubmed.ncbi.nlm.nih.gov
• FDA Announces Major Steps to Implement Real-Time Clinical Trials | FDAfda.gov
• Elixir sulfanilamide - Wikipediaen.wikipedia.org
• Biotech’s Lost Archive | IFPifp.org
• Biotech’s Lost Archive | IFPifp.org
• Canadian and US drug approval times and safety considerations - PubMedpubmed.ncbi.nlm.nih.gov
• Systemic Bottlenecks & Misalignmentscurecancer.ai
• FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests | FDAfda.gov